MAIA Biotechnology (MAIA) Net Income towards Common Stockholders (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Net Income towards Common Stockholders of -$6.4 million for Q1 2026, down 41.01% year-over-year from -$10.8 million in Q1 2025, and down 75.53% quarter-over-quarter from -$3.6 million in Q4 2025.
MAIA Biotechnology (MAIA) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$6.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 41.01% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at -$24.2 million (down 15.16% YoY), while the FY2025 annual figure was -$22.4 million, up 29.63% from the prior year.
- Net Income towards Common Stockholders declined to -$6.4 million in Q1 2026 per MAIA's latest filing, from -$3.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.7 million in Q3 2024 and bottomed at -$8.9 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$5.3 million across 5 years, with a median of -$4.9 million in 2023.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 44.01% in 2025 and fell as far as 225.41% in 2025.
- MAIA Biotechnology's Net Income towards Common Stockholders stood at -$4.1 million in 2022, then sank by 50.92% to -$6.3 million in 2023, then gained by 21.29% to -$4.9 million in 2024, then increased by 26.32% to -$3.6 million in 2025, then sank by 75.53% to -$6.4 million in 2026.
- Business Quant data shows MAIA's Net Income towards Common Stockholders at -$6.4 million in Q1 2026, -$3.6 million in Q4 2025, and -$8.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.94 Mn |
| Mar 31, 2026 | -6.37 Mn |
| Dec 31, 2025 | -3.63 Mn |
| Sep 30, 2025 | -8.90 Mn |
| Jun 30, 2025 | -5.35 Mn |
| Mar 31, 2025 | -4.52 Mn |
| Dec 31, 2024 | -4.92 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | -8.88 Mn |
| Mar 31, 2024 | -8.07 Mn |
| Dec 31, 2023 | -6.26 Mn |
| Sep 30, 2023 | -4.88 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -4.12 Mn |
| Dec 31, 2022 | -4.15 Mn |
| Sep 30, 2022 | -4.90 Mn |
| Jun 30, 2022 | -3.31 Mn |
| Mar 31, 2022 | -3.86 Mn |
| Dec 31, 2021 | -2.89 Mn |
| Sep 30, 2021 | -5.20 Mn |